Singapore: Cerecin, a clinical-stage biotechnology company pioneering neurotherapeutics, has closed the first tranche of a Series IIB financing round. The round was led by SK Securities and KNT Investment. Funds will be used to advance the current clinical studies of CER-0001 in migraine prevention and in infantile spasms (a rare form of pediatric epilepsy), finalize…
Home Healthcare Markets International Business Financing round-up: 5C Network, K Line Europe, Araris Biotech, Irubis, Cerecin